Topline results from the phase 3 LEVEL trial of TNX-103, an oral formulation of calcium sensitiser levosimendan, showed that the drug was unable to improve how far patients with pulmonary hypertension ...

Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.

Two Sarepta Therapeutics drugs for treating different genetic subsets of patients with Duchenne muscular dystrophy failed the confirmatory study required of their accelerated FDA approvals. Sarepta ...

Bayer’s Kerendia, already FDA approved in one cardiometabolic indication, now has data from a pivotal test that support expanding the drug’s label to heart failure. In preliminary results reported ...

Oliguric renal failure is a phase of acute renal failure (ARF), also known as acute kidney injury (AKI), in which a person’s urine output is very low. ARF is a sudden decline in kidney functioning.

Favourable safety profile in marked contrast to traditional inotropic therapeutics AC01 showed rapid and sustained numerical improvements in cardiac output, structure and function STOCKHOLM, Sweden, ...